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1. Introduction
Over the last four decades, healthcare costs in the United States have increased 31-fold from
$351 per person in 1970 to $11,582 in 2019.1 U.S. expenditures on healthcare are higher than
other developed countries. According to a study conducted by the Johns Hopkins Bloomberg
School of Public Health, the central reason for the larger expenditures in the United States is not
due to greater healthcare utilization, but rather, because of higher healthcare prices. U.S.
healthcare expenditures are expected to increase substantially, however, are likely to yield no
better results and in fact, could result in worse outcomes for consumers. 2 This trend will
intensify healthcare spending as well as the U.S. national debt and proves to be problematic
because the increase in spending has not yielded better health outcomes. National expenditures
are estimated to reach a whopping $6.2 trillion by 20283, leaving healthcare experts, public
policy economists, government officials, and American citizens concerned about the country’s
ability to provide acceptable levels of healthcare equitably and efficiently.
In addition to the dramatic rise in healthcare costs in the U.S., there has been an incredible
influx of healthcare technology which has contributed enormously to innovative and lifesaving
healthcare practices. The United States ranks fourth in the World Index of Healthcare Innovation
behind only Switzerland, Germany, and the Netherlands.4 Additionally, the United States is
almost always first in line to access new medical technology which is often pioneered by
American Universities and American companies. Yet, the U.S. ranks second to last in Fiscal

1Kamal,

Rabah, et al. “How Has U.S. Spending on Healthcare Changed over Time?” Peterson-KFF Health System Tracker, 16
Nov. 2021, https://www.healthsystemtracker.org/chart-collection/u-s-spending-healthcare-changed-time/.
2 “Why Are Americans Paying More for Healthcare?” Peter G. Peterson Foundation, 20 Apr. 2020,
https://www.pgpf.org/blog/2020/04/why-are-americans-paying-more-for-healthcare.
3 “NHE Fact Sheet.” CMS, 16 Dec. 2020, https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and
Reports/NationalHealthExpendData/NHE-Factsheet.
4 Roy, Avik. “United States: #4 in the 2020 World Index of Healthcare Innovation.” Medium, FREOPP.org, 25 June 2021,
https://freopp.org/united-states-health-system-profile-4-in-the-world-index-of-healthcare-innovation-b593ba15a96.
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Sustainability in terms of healthcare because the U.S. is the country with the largest amount of
government spending on healthcare per capita as seen through Medicare and Medicaid.5 The
2020 COVID-19 pandemic only exacerbated this issue as the U.S. government spent trillions of
dollars to support Americans battling the virus as well as Americans displaced from work. The
United States ranked number one in choice because of American’s access to leading medical care
technologies and high success rates despite being ranked fourteenth in terms of quality.6
This phenomenon of high healthcare costs and high technological innovation presents an
interesting problem. Popular economic theory teaches us that technological advancement
improves production efficiency, which shifts the supply curve to the left. As the costs of
production go down, consumers will demand more of the good or service at lower prices. In
other words, as technology increases, prices tend to go down resulting in lower prices and higher
demand for consumers. However, in the healthcare industry we are seeing the opposite occur.
Technological advancements are raising costs, which ultimately raises prices for consumers. At
the same time, consumers demand for healthcare is dramatically increasing. Many medical
professionals highlight progress in the medical field stemming from increasing usage of
sophisticated technology. However, such technology has proven to be expensive and beyond the
reach of everyday Americans. These patterns of rising costs and inefficiencies in healthcare exist
despite a robust push towards innovation, which implies that technology alone is unable to shift
the healthcare cost curve. Thus, the focus of my research will aim to provide an economic
analysis of the healthcare industry in the United States in terms of technological innovation,
transaction costs, and inefficiencies. If inefficiencies can be solved and more effective
technology implemented, I believe there is a way to advance modern medicine while

5
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simultaneously cutting costs for healthcare consumers and providers. Additionally, my research
will try and answer the question of whether the United States is unfairly bearing the burden of
healthcare technology costs? And if so, is the rest of the world free riding on U.S. healthcare
advancements?
1.1. Historical Development of Healthcare Costs
The modern healthcare system was created during World War II when President Theodore
Roosevelt regulated what U.S. employers could pay their workers by implementing wage
controls. However, the wage controls did not apply to work benefits such as health insurance, so
businesses began to offer much more competitive healthcare benefits to attract high quality
workers since they were limited with the Roosevelt wage controls. Moreover, in the 1950s the
Internal Revenue Service (IRS) excluded employer-based health insurance from federal, state,
and local taxation.7 Rapid adoption of health insurance followed and in turn, health care price
inflation skyrocketed. In 1965, the U.S. Congress passed the Social Security Act which created
Medicare and Medicaid, two medical care programs to help the elderly and the poor. The
combination of Roosevelt price controls, IRS tax codes, and the Social Security Act made
American consumers extremely price insensitive. The reason is that workers did not pay the
healthcare costs they used in the employer-based market, nor did they pay for the medical
insurance since it was purchased on their behalf by their employers. Therefore, they had no
incentive to limit their healthcare consumption which allowed for healthcare prices to start
increasing tremendously, without a reduction in demand.
On a per capita basis, health care spending has grown precipitously over the last half century.
In 1970, health spending totaled at $74.1 billion. By 2000, U.S. health expenditures reached $1.4
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trillion and as of 2019, the amount spent reached $3.8 trillion.8 This is a 31-fold increase and
marks one of the largest healthcare increases globally. Additionally, healthcare spending has
outpaced the growth of the U.S. economy. In 1970, 6.9% of GDP was allocated towards
healthcare spending according to data from both the Peterson Center on Healthcare and the
Kaiser Family Foundation. As of 2019, the amount of GDP spent on healthcare was 17.7%. 9 It is
common for health spending to increase during periods of economic downturn and has shown to
remain relatively constant during expansionary periods. Between the years of 2016 and 2019,
healthcare spending decreased slightly from 17.9% to 17.7% of GDP. This is likely attributed to
the economic expansion that the United States underwent during the Trump administration.
What’s more is that health spending also decreased throughout 2020 and the onset of the
Coronavirus pandemic. Several factors caused both spending and utilization to be driven down as
the pandemic hit the U.S. The primary factor is that in the spring of 2020, healthcare spending
decreased as elective surgeries and doctors’ appointments were cancelled. The push toward
telehealth did increase costs, but spending did not nearly increase as much as it would have had
the appointments been in-person. This trend continued throughout 2020, and the data has shown
that for the first time in history, health spending had dropped.10 However, as government
restrictions have been lifted, hospitals and healthcare facilities have begun to reopen and started
to conduct more elective surgeries which has brought healthcare spending up again.
Given the decrease in healthcare spending throughout 2020, data from the Kaiser Family
Foundation suggests that health spending is now on pace with economic growth in the United
States. Between 1970 and 1980, healthcare spending was growing at about 12% annually

Kamal, Rabah, et al. “How Has U.S. Spending on Healthcare Changed over Time?” Peterson-KFF Health System Tracker, 16
Nov. 2021, https://www.healthsystemtracker.org/chart-collection/u-s-spending-healthcare-changed-time/.
9 Ibid. pg. 4
10 Twitter, Cynthia Cox, et al. “How Have Health Spending and Utilization Changed during the Coronavirus
Pandemic?” Peterson-KFF Health System Tracker, 22 Mar. 2021.
8
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compared to an average annual growth of 9.3% of the U.S. economy.11 This is a large gap which
highlights the large increases in healthcare spending in the decades after the Roosevelt reforms
and Social Security Act. Following the 1980s, healthcare spending was still outpacing U.S.
economic growth, but at a smaller rate than in the 1970s. Looking to the periods between 2010
and 2013 as well as 2016 through 2018, the data shows that health spending growth was
homogenous to growth in GDP. Health spending did outpace GDP growth between 2014 and
2015, likely because of expansions to the Affordable Care Act by President Obama. 12 As of the
writing of this paper, healthcare spending is more on track with growth in U.S. GDP. Yet, the
issue of rising healthcare costs for both consumers and providers are still at the forefront of news
and a major talking point of politicians in Washington D.C.
1.2. Advancements in Medical Technology in Recent Years
Medical technology advancements over the last fifty years have entirely reshaped the practice
of medicine in the United States. It has also saved countless lives, increased access to care, and
improved the quality of life for Americans. Traditional healthcare systems have faced heavy
criticisms for a reactionary approach to healthcare. The U.S. indeed maintained a reactionary
healthcare approach for much of the early 1900s and through the industrial revolution. That is,
health issues are not addressed until they become problematic. However, as the U.S. began to
implement increased accessibility of healthcare during the 1960s the focus of medicine changed
to a more proactive approach. This proactive approach paired with advancements in healthcare
technology allowed doctors to treat patients at the onset of their illnesses rather than wait until it
was too late. For example, the creation of the full-body MRI has allowed doctors to detect bodily
abnormalities before symptoms occur and begin to treat the problem before it gets out of control.

“KFF Analysis of National Healthcare Expenditures (NHE) Data.” CMS, 16 Dec. 2020, https://www.cms.gov/ResearchStatistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsHistorical.
12 Ibid. pg 6
11
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Similarly, new cancer blood tests can detect over fifty different forms of cancer. Innovations like
these have allowed the U.S. healthcare system to begin taking a proactive approach to healthcare
and undoubtedly has contributed to the U.S. success rate in curing patients. Another
advancement in the U.S. healthcare system has been a push for more personalized healthcare.
Given that medical technology can capture billions of data points, doctors are becoming much
better at creating individual pictures of a person’s health and able to take a better approach at
tackling health issues. This advancement in data collection highlights the U.S. healthcare shift to
a more holistic and individualistic approach to medicine.
A third healthcare advancement is the convenience of care patients experience. Early in the
United States healthcare system, there were long wait times to meet with a physician or have
surgery done. The same can be said about countries like Canada and Sweden who operate on a
socialized healthcare systems that causes wait times to be much longer, and the quality of care to
be much worse for patients. In the U.S., healthcare companies operate on the same incentives
that companies in other sectors do. Time is money, so healthcare providers have begun to look
for more efficient and effective ways to see patients. A great example is greater hospital turnover
rates. Patients are no longer burdened by long wait times or piles of confusing paperwork.
Evidence of this has been a shift towards telemedicine. Telemedicine has allowed providers to
have greater turnover times, see more patients, and has limited the congestion of hospitals and
waiting rooms with an influx of patients. Telemedicine has also made it easier on patients to see
a doctor faster and reduce travel costs associated with getting to a hospital or care center. The
United States has come incredibly far in their healthcare advancements which has been no small
feat. These technological advancements will continue to develop and advance, giving patients
and doctors better resources to fight the illnesses and diseases they face. But again, despite the
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wonderful advancements we’re seeing in the U.S. healthcare system, the cost of healthcare is still
an issue which makes us question if the technological advancements are growing too fast?
2. Literature Review
Thomas Bodenheimer, professor of Family Community Medicine at the University of
California, San Francisco, offers several explanations for rising healthcare costs: (1) high and
rising costs are created by forces outside the healthcare system. (2) the weakness of a
competitive free market within the health system. (3) the rapid diffusion of technology. (4) the
absence of strong cost-containment strategies. And (5) undue market power of health care
providers. In this article, Bodenheimer aims to answer, “Are high and rising health care costs a
serious problem?” “Are rising costs explained by factors outside the health care system?” And
“does the absence of a free market in health care explain why costs are high and rising?” These
are great questions to ask and answer in understanding the flaws of the U.S. healthcare system
and how we can fix the flaws that contribute to rising healthcare costs. A follow-up article by
Bodenheimer addresses medical technology and innovation in the United States and how it
applies to rising healthcare costs. Bodenheimer posits that technologic innovation, in
combination with weak cost-containment strategies is a major factor in rising healthcare costs in
the United States. He goes on to contrast different health systems globally and the effects
technology plays across the world.
Gail R. Wilensky, an economist and senior fellow at Project HOPE, published an article
titled Technology as a Culprit and Benefactor in the healthcare sector. For Wilensky, medical
technology can be seen as a mixed blessing: on the one hand, rising costs. On the other hand,
improved diagnosis, treatment, and health status. Wilensky’s article discusses the influence of
key factors on the demand for healthcare technology and its utilization. According to Wilensky,
such factors include rising health expenditures, changes in populations, and the development of
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cost containment strategies. Additionally, shifts in consumer incentives and utilization are
examined. Similar to Wilensky’s article, an article from Paul Wallner and Andre Konski, both
medical doctors, looks at the impact of technology on healthcare costs and policy development.
This article references that some health care economists have suggested that “the rapid
introduction of new technologies has also played a major role” in the rising cost of health care.
Medical equipment vendors often have the desire to for early market penetration of their
products which is often accomplished before any cost-benefit analysis can be performed on the
new technology. The current system of technology approval has produced further disruptions to
cost inflations. The nature of this problem will be covered in this article as well as the various
factors in the introduction, implementation, and evaluation of new medical technology.
In recent years, concerns have risen in the United States over rising health care costs has led
to reductions in the lengths of hospital stays for patients. Perceptions of this compromised
medical care phenomena have led to regulators to call for more strict regulation of insurance
companies. Yet little attention has been paid to the actual benefits and costs of reducing the
lengths of hospital stays for patients and therefore decreasing hospital costs. This paper by
Kathleen Carey provides empirical evidence on how shorted hospital stays can lead to declining
costs for hospitals. Carey’s method utilizes a total operating cost function of 2,792 different
hospitals in the United States between 1987-1992. There are three different estimating
techniques including a random effects model, circumventing inconsistency problems, and the
cost elasticity of the hospital stay. Carey’s findings suggest that common perceptions regarding
the extent of cost savings resulting from length of stay reductions have been overestimated.
Mark McClellan, director for the Engelberg Center for Health Care Reform, focuses on the
movement towards a radically different approach to paying healthcare providers in his paper

11
Reforming Payments to Healthcare Providers: The Key to Slowing Healthcare Cost Growth
While Improving Quality? McClellan suggests “these reforms seek to create direct linkages
between payments to healthcare providers and measures of the quality and efficiency of care”
(70). McClellan gives an overview of payment reforms for healthcare providers and their welfare
implications through a wide range of empirical studies. The small-scale studies cited in this
paper suggest that provider payment reforms in accordance with greater attention to improving
measurements of care quality, can have a substantial impact on the quality of care and in some
cases even reduce the resources and costs to such care.
Lastly, an article by Stuart Butler, senior fellow in Economic Studies at The Brookings
Institution, titled, Containing Health Costs in a Consumer-Based Model takes a defensive
argument against the idea that consumer choice is not relevant in the healthcare system cost
structure. Butler argues that “the assumption that consumer choice cannot be used to achieve cost
control in health care is invalid. It does not do so today because the tax treatment of health care
leads to perverse consumer incentives that encourage cost escalation” (21). Stuart believes that it
is possible to design a universal system that is efficient and allows for consumer choice to be a
powerful constraint on healthcare costs which could be a powerful means for reforming the
healthcare system in the United States.
3. Analysis
The first question we must answer in our investigation of rising medical costs in the United
States is, “should rising healthcare expenditures be a serious concern? Or are American’s over
analyzing the state of healthcare in the U.S?” The answer lies in how you approach the question.
Many medical professionals as well as healthcare economists have taken the position that rising
healthcare costs are not as serious of a problem as popular media has made it out to be. Mark V.
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Pauly, an American Economist, has been particularly vocal about healthcare costs being less
worrisome than other economic forces. His work has often cited that high healthcare
expenditures correlate to better health outcomes for patients, more jobs, higher incomes for
providers, and most importantly, it reflects a high demand from consumers who are willing to
pay.13 While this may be true in some respects, it does not reflect the opinion of the millions of
payers whether that be organizations or individuals. Most employers want to see a reduction in
healthcare costs because they are responsible for providing healthcare benefits to their workers.
As healthcare gets more expensive, firms hire less workers, give less bonuses and raises, and in
the worst cases, must lay off workers because they cannot afford the increased costs of
healthcare benefits.14 If healthcare costs were lower, it would make sense that firms would be
able to increase employee salaries, reduce prices of their goods and services, or increase profits
for shareholders. All three of these events have a greater impact on the overall economy than
increased healthcare costs.15 What’s more is that increased federal expenditure on healthcare
creates massive budget deficits, and leads to reduced spending for education, infrastructure,
technology, police, and other public goods.16 Therefore, increased health expenditures can create
negative externalities for employers, employees, and governments that affect not only
individuals, but also the economy as a whole. Thus, this paper proceeds with the belief that rising
healthcare expenditures are a serious concern and should be dealt with accordingly.
Knowing that rising medical costs are a serious problem, it’s important we analyze the
determinants of rising medical costs so we can better understand the root causes, to then be able

13

Pauly MV. Should we be worried about high real medical spending growth in the United States? Health Aff (Millwood). 2003
Jan-Jun;Suppl Web Exclusives:W3-15-27. doi: 10.1377/hlthaff.w3.15. PMID: 14527232.
14 Gabel J, Levitt L, Holve E, Pickreign J, Whitmore H, Dhont K, Hawkins S, Rowland D. Job-based health benefits in 2002:
some important trends. Health Aff (Millwood). 2002 Sep-Oct;21(5):143-51. doi: 10.1377/hlthaff.21.5.143. PMID: 12224876.
15 Davis, K., Anderson, G., Renn, S. C., Rowland, D., Schramm, C. J., & Steinberg, E. (1985). Is cost containment
working? Health Affairs, 4, 81–94.
16 Ibid. pg. 9
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to offer solutions. A 2017 Journal of the American Medical Association (JAMA) study listed
five determinants of rising healthcare costs: (1) population growth, (2) population aging, (3)
disease prevalence or incidence, (4) medical service utilization, and (5) service price and
intensity.17 Results from the study cited that each determinant played a considerable role in rising
expenditures between 1996 and 2013. Yet, the strongest determinant out of the five was service
price and intensity which had the largest impact on healthcare costs over the seventeen-year
study. Service price and intensity essentially looks at the price of service and the intensity or rate
at which patients seek care. The study undoubtedly gives us good insights into key determinants
of healthcare costs but fails to include technology as a major source of rising costs. In terms of
this paper, I will prove that technology is a key determinant of rising healthcare costs and
investigate why technological advancements have led to higher costs for healthcare while not
simultaneously lowering prices.
3.1. Technology as the Key Determinant of Rising Healthcare Costs
The American healthcare system has a difficult relationship with technological
advancements. On the one hand, technology is praised for saving lives, improving health
outcomes, and improving quality of care. While on the other hand, technology has been
villainized as a proponent in the increased cost of healthcare. Major medical technologies such as
magnetic resonance imaging (MRI) systems are both hailed for their medical success and blamed
for their cost basis. It’s clear that technology in the medical field teeters on a fine line between
good and evil and for good reason. Peter Neumann and Milton Weinstein emphasize this point in
their book The Changing Economics of Medical Technology which outlines five facts of medical
technology that helps illustrate the causes and effects technology plays in increased healthcare

JAMA: Journal of the American Medical Association. “Factors Associated with Increases in US Health Care Spending,
1996–2013.” Accessed March 9, 2021.
17
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costs. The first fact is that new technologies do improve healthcare outcomes.18 It is true that
better medical technologies lead to quicker diagnoses of illnesses and diseases and can lead to
better preventative measures to keep people healthy and living longer. The second fact is that a
lot of new technologies are either redundant or ineffective when they are introduced.19 Meaning
some new technologies are technologies that already exist but are marketed as new and improved
devices that serve no real purpose and don’t lead to significantly better health outcomes.
The third fact is that on average, new technologies do add to healthcare costs.20 While it’s
important to note that some technologies do decrease costs, the average technology when
brought to market raises healthcare costs. This is a simple concept to understand. New
technologies are more expensive because one, their new and improved and thus have greater
value, and two they tend to provide better results, which also reflects greater value and ultimately
a higher price. However, this higher price is not borne by the providers, rather it is passed off
onto patients and payers who in most cases have no choice but to use the technology. This has a
compounding effect as millions of patients seek such technologies and contributes to a
tremendous increase in healthcare spending. The fourth fact is that the healthcare sector
encompasses an inadequate diffusion of technologies.21 In other words, the American healthcare
sector has an underdiffusion of cost-effective technologies and an overdiffusion of ineffective
technologies. And the fifth fact highlighted by Neumann and Weinstein is that Americans cannot
get enough of new medical technologies.22 The demand for new and improved technology lies at
the heart of the American consumer and the healthcare system is no exception to that.

18

Institute of Medicine (US) Committee on Technological Innovation in Medicine. The Changing Economics of Medical
Technology. Edited by Annetine C. Gelijns et. al., National Academies Press (US), 1991. doi:10.17226/1810
19 Ibid. pg. 21
20 Ibid. pg. 22
21 Ibid. pg. 23
22 Ibid. pg. 23
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So how much does technology add to healthcare expenditures? Research has shown that
new and existing medical technology is a contributing factor to rising medical costs.23 However,
many researchers have had trouble identifying the extent to which technology raises costs. The
difficulty lies in defining and categorizing medical technology. Medical technology has
historically encompassed drugs, devices, surgeries, and hospital support systems.24 Yet
identifying the advancements in technology and attributing them in an economic sense is
incredibly difficult to do. Another important aspect of medical technology is that the economic
impact of medical technology is often misconstrued to mean the purchase price of the piece of
equipment or the cost of the surgery. This is not the case. The total impact of medical technology
on healthcare prices reflects the both the initial capital costs of producing and implementing the
technology as well as the operating costs it takes to continue to use the technology. Quantifying
the capital costs of technology is easy, and studies have shown that capital costs of medical
technology make up a good portion of healthcare costs.25 The difficulty of quantifying costs
comes from operating costs of technology which varies across virtually every hospital, clinic, or
facility in the country. But it’s reasonable to assume that the operating costs of health technology
is more than capital costs given the need for operating staff, supervisors, advanced training, and
maintenance. To make the issue even more complex, technology costs are not only a function of
their capital and operating costs. They also include the utilization of other health services and
technologies. For example, a new body scanning technology may lead doctors to diagnose an

Stuart H., and Robert Blendon. Medical Technology -- the Culprit behind Health Care Costs : Preoceedings of the
1977 Sun Valley Forum on National Health. Dept. of Health, Education, and Welfare, Public Health Service, Office of Health
Research, Statistics, and Technology, National Center for Health Services Research, 1979. EBSCOhost,
search.ebscohost.com/login.aspx?direct=true&db=cat02507a&AN=ohiolink.b13167143&site=eds-live.
24
U.S. Congress, Office of Technology Assessment. Strategies for Medical Technology Assessment. GPO Stock No. 052-00300887-4, Washington, D.C.: U.S. Government Printing Office, 1982.
25Altman, Stuart H., and Robert Blendon. Medical Technology -- the Culprit behind Health Care Costs: Preoceedings of the 1977
Sun Valley Forum on National Health. Dept. of Health, Education, and Welfare, Public Health Service, Office of Health
Research, Statistics, and Technology, National Center for Health Services Research, 1979. EBSCOhost,
search.ebscohost.com/login.aspx?direct=true&db=cat02507a&AN=ohiolink.b13167143&site=eds-live.
23Altman,
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illness that requires other technologies to heal or confirm the original diagnosis.26 Technological
procedures may lead to further tests or procedures that have a compounding effect on healthcare
costs.
As previously stated, placing an amount on cost of healthcare from technology is
difficult. However, some researchers have been able to estimate the costs of healthcare from
other easily identifiable factors, such as population growth or population aging to then give a
better estimate of the role technology plays. Similar to how the Journal of the American Medical
Association highlights the five determinants of rising healthcare costs, Karen Davis, a professor
of Health Policy and Management at Johns Hopkins Bloomberg School of Public Health,
hypothesizes that the portion of medical expenditures not accounted for by the five factors
JAMA highlights can be attributed to technology.27 Davis’s work helps us pinpoint the area for
which technology costs should be reflected. Davis also concluded that technology led to a 25
percent increase in hospital expenses between 1962 and 1968.28 Additionally, a study conducted
by researchers at the Sun Valley Forum on National Health used empirical evidence to suggest
that technology accounts for 10 to 40 percent of increased medical costs over time.29
It’s worth noting that a contradicting view from authors Thomas W. Moloney and David
E. Rogers, M.D. who published an article in the New England Journal of Medicine arguing that
major technologies such as MRI’s or CT scans account for much less growth in health costs than

26

Weinstein MC, Read JL, MacKay DN, Kresel JJ, Ashley H, Halvorsen KT, Hutchings HC. Cost-effective choice of
antimicrobial therapy for serious infections. Journal of General Internal Medicine 1986; 1 351-363.
27 Mark Perlman (ed.), 1974. "The Economics of Health and Medical Care," International Economic Association Series, Palgrave
Macmillan, number 978-1-349-63660-0, September.
28 Ibid. 283
29Altman, Stuart H., and Robert Blendon. Medical Technology -- the Culprit behind Health Care Costs: Proceedings of the 1977
Sun Valley Forum on National Health. Dept. of Health, Education, and Welfare, Public Health Service, Office of Health
Research, Statistics, and Technology, National Center for Health Services Research, 1979. EBSCOhost,
search.ebscohost.com/login.aspx?direct=true&db=cat02507a&AN=ohiolink.b13167143&site=eds-live.
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smaller tests and procedures.30 Empirical evidence shows that a 50 percent reduction in operating
costs of major medical equipment would only yield between a 1 and 2 percent reduction in
national healthcare expenditures. 31 While the authors make the 1-2 percent decline in
expenditures out to be a small number, in reality, the cost savings would equate to between $12
and $25 billion in national expenditure savings. So, while technology costs may not seem as
large in percentage terms, monetarily the savings could be huge.
3.2 The Efficient Level of Technology
Knowing that technology increases healthcare expenditures and costs for consumers,
even if by only a few percentage points, it’s important to attempt to find an optimal level of
technological output that helps to promote health outcomes while also reducing health costs.
First, in order to be able to determine the optimal amount of medical technology, it’s important
to first have a clear assumption to the goal of healthcare technology. For this paper, I am
assuming the goal of technology to be improved healthcare outcomes. Neumann and Weinstein
share this assumption in their book, which has helped me base my argument. Second, it’s
important to note the diminishing marginal returns to medical technology. Just as economic
theory cites, diminishing marginal returns tells us that each additional unit of production results
in smaller increases in output. For example, the first investment in medical technology will yield
better health outcome than the tenth investment. Thus, it’s important for us to find the point of
maximum yield for technology in hopes that it will drive down healthcare expenditures and pass
that savings off to consumers. Milton Weinstein in a separate work titled Foundations of Costeffectiveness for Health and Medical Practices devises a formula for measuring the optimal level

Moloney, T W, and D E Rogers. “Medical technology -- a different view of the contentious debate over costs.” The New
England journal of medicine vol. 301,26 (1979): 1413-9. doi:10.1056/NEJM197912273012603
31 Ibid. 61
30
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of medical technology. In his cost-effectiveness analysis, Weinstein compares net healthcare
costs to net healthcare benefits. He concludes that if a new technology produces better health
outcomes at lower costs per unit than current technologies, then the new technology should be
adopted, if not, then it should be rejected
.32 Weinstein’s cost-effectiveness analysis shows promise in the health community as an
oversupply of ineffective technology plagues the system and leads to incredible inefficiencies
which correlates to wasted costs. Yet, Weinstein hasn’t been the only proponent of implementing
a cost-effectiveness analysis to healthcare technologies. Cost-effectiveness analyses have been a
growing practice and has gained widespread acceptance in the healthcare community as the
appropriate mechanism for analyzing technology costs.33
One of the pioneering examples of this cost-effectiveness analysis in healthcare was done
by a group of researchers on the cost-effectiveness of hemodialysis in end-stage renal failure.34
The study was able to project a low cost per year of hemodialysis compared to other technologies
that fight end-stage renal failure. Researchers also inferred that the study was probably the
deciding factor for Congress to include end-stage renal failure under universal coverage for
Medicare.35 Yet, cost-effectiveness analyses do present some challenges and limitations. The
primary limitation being that most new medical technologies are adopted before significant data
is available for cost-effectiveness analyses. 36 A larger limitation to widespread adoption of costeffectiveness analyses is that the diffusion of medical technologies often leads to ineffective

Weinstein, M C, and W B Stason. “Foundations of cost-effectiveness analysis for health and medical practices.” The New
England journal of medicine vol. 296,13 (1977): 716-21. doi:10.1056/NEJM197703312961304
33 Eisenberg, J M. “Clinical economics. A guide to the economic analysis of clinical practices.” JAMA vol. 262,20 (1989): 287986. doi:10.1001/jama.262.20.2879
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health outcomes. That is, a cost-effective technology will diffuse into other areas of healthcare
where the technology is obsolete or ineffective. This in turn presents challenges for developers,
utilizers, practitioners, and patients of new technology. The challenge becomes allowing for the
adoption of cost-effective technologies in areas where they create net positive health outcomes,
without letting the technologies bleed over into areas where they become cost ineffective.37
How then can the medical community achieve better health outcomes in the future while
simultaneously reducing healthcare expenditures? Research suggests that cost-effectiveness
analyses be the determining criteria for the adoption of new healthcare technologies. That’s not
to say other criteria such as population growth, population aging, disease prevalence, medical
service utilization, and service price intensity be excluded, they too need to be analyzed. But a
strong cost-benefit analysis of technology must also be in the conversation around rising health
expenditures. Implementing cost-benefit structures will be no small feat of course but is
necessary for the future of healthcare. Currently there is no strict funding allocated towards this
type of research in the United States. The first step towards improvement is to allocate sufficient
funding towards cost-effectiveness research to help gain better perspectives on the types of
technology that are leading the medical industry and whether they are worthy of their costs.
Second, as Neumann and Weinstein describe, the incentive structure facing healthcare providers,
insurers, and consumers all need to shift towards cost-reduction and resource constraints.38 Most
providers have begun to move towards better cost-reducing technologies or systems, but insurers
and consumers are still facing disconnect. Thus, a unilateral shift towards cost-prevention and
increased health outcomes must be put in place if this country wants to get any sort of grip on
radical healthcare costs. Lastly, we cannot ignore the demand of the American public. Americans
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want newer and better technologies to improve health status, but at lower prices. Therefore,
being able to improve the system to reward cost-effective healthcare and promote new costeffective technologies could dramatically improve these goals.39
3.3 Why Does Healthcare Cost So Much for Americans?
The United States has historically spent significantly more on healthcare than comparable
OECD countries. In 2018, the U.S. spent nearly twice as much per person as other OECD
countries according to data from the Kaiser Family Foundation.40 Researchers from Health
Systems Tracker analyzed data from 2018 on 10 OECD countries to come up with figures on
health spending, and percentages of spending by health category.41 The largest category of health
spending came from spending on inpatient and outpatient care. This includes payments to
hospitals, clinics, and physicians. Looking at country by country comparisons, health costs in the
U.S. were $5,110 more per person in comparison to other OECD countries. It’s clear that
inpatient and outpatient care represent a much larger share of spending than other similar
countries.42 Figure 1 represents this spending discrepancy. Moreover, the growth rates in
spending the U.S. have seen over the past decade reflect similar rates across the board, but
widely different amounts of money. Figure 2 represents this.
Popular economic literature surrounding rising healthcare costs has attributed some of the
blame towards the presence of market power for healthcare providers and insurers. The
American healthcare system since its inception has had strong barriers to entry. It’s no secret that
providers must go through nearly a decade of schooling, amass on average a quarter of a mullion
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dollars of debt, and still be required to meet certain criteria just to practice in the United States.
These high barriers to entry create a systematic issue that causes fewer Americans to pursue
careers in healthcare and ultimately gives universities, providers, and insurers the power to
charge high prices for education and medical care.
In July of 2021, the International Monetary Fund published an article by Li Lin and Mico
Mrkaic titled U.S. Healthcare: A Story of Rising Market Power, Barriers to Entry, and Supply
Constraints. The authors cite evidence of market power and competition in the U.S. healthcare
industry though estimating the true strength of market power, the impact of market power on
healthcare spending, and an analysis of the Affordable Care Act (ACA) and its role in defining
healthcare wages. According to the article, price markups for publicly listed healthcare providers
have nearly doubled since 1980.43 Using data from over 81,000 publicly listed firms, which
accounts for 99% of the global healthcare market capitalization, the authors found that U.S.
healthcare firms have been able charge much larger markups than other firms across the globe.
The U.S. markup has been nearly 70% since 1980 compared to 40% in other healthcare sectors.
Figure 4 of the Appendix highlights their findings.
The dramatic increase in markups in the U.S. has had a resounding effect on the
healthcare spending throughout the country. Based on the authors regression models, markups
account for roughly a quarter of annual increased in U.S. real health spending since 1980.44
What’s more is the role the ACA has had in recent years on real healthcare wages. Gruber and
Sommers (2019) find strong evidence that the positives of the ACA have been increased
insurance coverage for Americans.45 This has also correlated to a positive relationship between
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access and consumption. I.e., a larger number of Americans being insured has led to greater
access to care and therefore, greater utilizations. Given the expansions provided by the ACA, Lin
and Mrkaic found that between 2016 and 2019 average wages in Medicaid expansion states grew
by 75% faster than non-expansion states.46 Real wages had a compounding effect for providers
in expansion states compared to non-expansion states. But with that came higher prices for
service and care. Figure 5 of the Appendix highlights the researchers’ findings. So again, we see
a relationship between wages and prices which benefit providers but hurt consumers. It also
reaffirms the role of market powers and how public policy can exacerbate these issues despite
campaigning to cut healthcare costs.
While market power and barriers to entry are certainly a defining force behind medical
costs, a lot of the cost born by Americans comes from the innovations that the American
healthcare system makes. Most health economists believe that technological advancements are
correlated to higher health expenditures.47 But the price Americans pay for healthcare is also
largely a function of the innovations that take place within U.S. borders and how that innovation
affects the price of healthcare. Medical innovations require more capital, labor, and higher
expenses.48 All of these inputs to medical innovation cost money, and lots of it which leads to
higher prices for consumers especially in the United States. Moreover, greater innovation leads
to greater access, which is undoubtedly a positive for Americans seeking care. But with
increased access comes increased utilization. Higher levels of utilization lead to higher costs.
That is, greater accessibility for Americans leads to greater per capita use and greater per capita
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spending on healthcare.49 Thomas Bodenheimer, MD author of High and Rising Health Care
Costs, writes “innovation has spread more widely and has commanded higher prices per unit of
service in the United States compared with most other developed nations.”50 Take for example
the fact that the U.S. houses twice as many MRI machines per capita compared to every other
developed nation. Or what about the fact that by the turn of the 21st century, the United States
had twice as many coronary bypass surgeries per capita than the top 15 developed nations.51
U.S. acceptance of major medical technologies is major reason for the rapid diffusion of
technology across health systems throughout the country. Physicians in the U.S. qualify patients
ready for treatments by major medical technologies and new procedures at a much faster rate
than comparable countries. This is partly due to the fact that providers are paid on a fee-forservices basis, so doctors have an incentive to use the latest technologies and run the most tests
so they can get the highest payouts. However, the rate at which innovation is spreading is also
correlated with the number of specialists in an area.52 Specialists demand the latest and greatest
technology to attract more clients and thus more income. So, specialists will seek out more
technology and spending from their hospitals which leads to higher spending per capita and thus
higher costs per capita. A leading question we might ask is whether this rapid diffusion of
innovation is being pioneered by physicians, hospitals, and technology entrepreneurs, or is this
being demanded by the American public? A survey between American and Canadian citizens
found that citizens of both countries had greater expectations and awareness to medical
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innovations than did citizens of Western European nations.53 It’s clear that public sentiment
plays a large role in the access and diffusion of medical technologies in the U.S. which may be
yet another reason for the U.S. being the highest payer for healthcare in the world. However, it
may also allude to the vast amounts of media and marketing for medicine that take place in the
U.S. and suggest that a lack of regulation around medical advertising may play a larger role in
the diffusion of technology and innovation. Regardless, the U.S. remains at the top of global
charts for healthcare spending per capita. This high spending is largely a function of high
consumer demand for healthcare, technological innovations, and diffusion of technologies. Most
Americans have access to revolutionary medical technology which they are certainly paying for.
Which poses the last question of my thesis. And is the rest of the world free riding on U.S.
innovations while Americans get left with the bill?
3.4 Foreign Free-Riders?
Prior to the 2020 COVID-19 pandemic Albert Bourla, chairman and CEO of Pfizer,
petitioned to former U.S. President Donald Trump to fight harder for price controls of
prescription drugs in foreign countries. More so, Bourla said that foreign nations are “free-riding
on American innovation” during a U.S. Senate hearing regarding high U.S. drug prices. Bourla’s
proposal was one of many put forth by the pharmaceutical industry but fell on deaf ears when
Senators fired back stating that the pricing set by drug companies are “unacceptable.”54
However when before a Senate judiciary hearing, top drug makers defended their pricing
strategies citing that they’ve actually been receiving less in recent years for their drugs than they
have historically.55 Yet study from the research firm IQVIA found that between 2012 and 2017,
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prices of brand name prescriptions rose by 60%.56 In an attempt to ease this burden on
consumers, lawmakers have begun to focus on easing the approval of rival drugs to drive down
prices or consider importing from different countries. This came with some pushback from
Bourla and other executives in the pharmaceutical industry with Bourla stating, “the [Trump]
administration should try for trade agreements to protect American innovation. These price
control mechanisms of multiple well-developed countries is in reality a free riding on American
innovation.”57 It is true that prices of drugs in many well-developed European nations are
cheaper than in the United States. This is mostly attributed to government regulation and
intervention matched with greater competition across the industry. But the case still needs to be
made whether Americans are getting the short end of the medical innovation stick.
There has been a campaign going on since the early 1990’s advocating for U.S.
protection from foreign free-riders.58 This movement, while heavily backed by the
pharmaceutical industry, has grown in favor from millions of Americans and been the focal point
of numerous Senate Committee hearings on Health. The movement has urged U.S. policymakers
to step in and demand foreign countries pay more for the drugs and technologies founded in
America. The primary argument from supporters of foreign countries paying more is that foreign
countries do not have to pay for the research and development costs that are associated with the
development of drugs and medical technology which gives these countries the ability to put price
controls on medicine into place. Thus, Americans have to pay the costs of innovation through
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higher healthcare prices so the rest of the world can continue to be supplied with the latest and
greatest American technology and drugs. 59
Donald W. Light, a researcher and professor of Comparative Health Care at Rowan
University School of Osteopathic Medicine, seems to take an opposing view to the idea that
Americans are getting scammed by the rest of the developed world. In his article, Foreign Free
Riders and the High Price of US Medicines, Light suggests that there is no data supporting the
idea that foreign countries do not pay for research and development of new drugs. 60 In fact, in
the latest available report from the United Kingdom Pharmaceutical Price Regulation Scheme,
data suggests that drug companies in the UK invest considerably more of their revenues in
research and development than companies in the U.S.61 This suggests that lower prices in
affluent foreign nations many not necessarily mean less research and development. Yet, Mark
McClellan, former commissioner of the FDA has claimed that low prices in foreign nations are
slowing the growth of drug development around the world. 62 Light presses McClellan’s claim
citing data from the European Federation of Pharmaceutical Industries and Associations that
showed from 1990 to 2003 members of the European Federation increased R&D spending over
two-fold while the U.S. increased spending four-fold.63 This directly contradicts McClellan’s
claim that R&D is slowed by lower prices in foreign nations. It does however show that R&D
spending grew at a larger rate in the U.S., but researchers from the European Federation
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explained this to be a function of the regulatory framework around medicine in Europe, spending
conditions, and societal perspectives on new medical technologies.
In fact, several developed countries spend nearly as much as the U.S. does on R&D.
Figure 3 highlights spending on research and development as a percentage of gross domestic
product across well-developed countries as of 2020. Pharmaceutical companies in Europe
allocate large percentages of revenue towards R&D just as in the United States. This has been
ignored by the foreign free-rider campaign and contradicts their claim that somehow major
developed countries are deliberately using the U.S. for healthcare innovation. The campaign’s
ideas of foreign free riders may come from a lack of understanding of the truth behind the
economics of drug development. I myself am guilty of believing and trying to prove that
foreigners are free riding on U.S. medical innovations. However, I’ve been proven wrong.
Donald Light cites three different ways of why foreign free riding is a myth.64 The first being
that the development of most pharmaceutical drugs as well as healthcare technologies comes
from innovations in multiple countries, not just the United States. Second, fixed costs, like R&D,
do not determine market prices. 65 Prices are set by the market, therefore the issues like R&D and
innovation, while they are relevant to development, are not relevant to prices. The reason that
prices are high are because of patents that major drug companies get which gives them monopoly
power over the competition and thus the ability to mark prices much higher. Therefore, the
blame should be placed on the massive drug companies pushing the foreign free-rider narrative.
If costs are to come down, it starts with regulating and investigating major drug and technology
companies. And third, the “free-rider problem” is easily misconstrued and can easily get media
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attention because people, especially Americans, don’t like to feel like they’ve been beaten or
one-upped. Thus, its easily to convince people of the narrative that the problems we face here
with high medical prices is because of foreigners stealing our innovation. It’s a much easier pill
to swallow than the idea that the companies in the U.S. are responsible for one-upping
Americans into paying steeper prices for drugs and technology.
4. Conclusion
The healthcare industry has provided unimaginable amounts of invaluable medicines,
technologies, and innovations that have saved tens of millions of lives since the inception of
modern medicine. The introduction of technology has skyrocketed innovation and led to rapid
growth in development which has led to the curing and improvement of many diseases and
illnesses. The immense good that healthcare has brought for humans has been an incredible feat
for mankind. But the industry is not without its flaws. While technology has played a large role
in the growth of the healthcare industry in the United States, it’s also operating at an inefficient
level. The U.S. is not producing technology in a cost-effective way which is leading to an
oversupply of technology, inefficiencies, and wasted costs. Looking through a lens that identifies
technology as being the key determinant of rising healthcare costs, we’ve seen that an inefficient
level of technology leads to massive costs which get passed off onto the consumer in the form of
higher drug prices. Moreover, monopoly power from major drug and tech companies has given
them the ability to price drugs and medical technologies as they see fit which has caused prices
for Americans to become out of control. All of this is happening while a narrative of foreign free
riders gets pushed, primarily from drug and tech companies setting prices, to convince
Americans the problem resides elsewhere. What I’ve concluded is that the U.S. healthcare
system is incredibly complex and faces lots of uphill battles in the fight against high prices. But
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it's not unachievable. The first step would be to utilize a cost-effectiveness approach when
implementing new technologies. This would help cut out cost-absorbing technologies and
promote cost-cutting ones. The second step would be to get a better grasp on the diffusion of
technology and innovation, so it does spiral out of control. And third, drug and tech companies
need to be regulated more and medical monopolies need to be broken up so that competition can
flourish and drive down real prices of drugs and medical technology. If these objectives can be
met, I believe that Americans would see a reduction in the price they pay for healthcare.
Moreover, the market for healthcare can begin to push back towards market equilibrium so
efficiency can be achieved for all parties involved.
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